WG
RCKT icon

Winton Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Winton Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52K Sell
15,200
-27,300
-64% -$90.8K ﹤0.01% 1122
2026
Q1 		$152K Buy
+42,500
New +$169K 0.01% 1009
2020
Q1 		– Sell
-18,882
Closed -$430K – 1514
2019
Q4 		$430K Buy
+18,882
New +$315K 0.01% 1284

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Winton Group's RCKT Position: Q2 2026 in Review

Winton Group reduced its Rocket Pharmaceuticals (RCKT) stake by 64% in Q2 2026, selling an estimated $90.8K and leaving 15,200 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #1122.

Winton Group first reported a position in RCKT in Q4 2019 and has held it in 3 quarters since. The position peaked at $430K in Q4 2019. 179 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Winton Group held 15,200 shares of Rocket Pharmaceuticals worth $52K as of Q2 2026.
  • Winton Group sold 27,300 Rocket Pharmaceuticals shares in Q2 2026, an estimated $90.8K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1122 holding.
  • Winton Group first reported a position in Rocket Pharmaceuticals in Q4 2019 and has held it in 3 quarters since.
  • Winton Group's Rocket Pharmaceuticals position peaked at $430K in Q4 2019.
  • 179 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.